RxDoctor Payments Data

Christine Edmondson

Psychiatric/Mental Health · Astoria, NYNPI 1477973519

Payments from drug & device makers

$2,229in general payments, 2019–2025

Across 72 payments — averaging $30.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$518
  • Otsuka America Pharmaceutical, Inc.$281
  • Teva Pharmaceuticals USA, Inc.$275
  • E.r. Squibb & Sons, L.L.C.$248
  • Vanda Pharmaceuticals Inc.$209
  • Neurocrine Biosciences, Inc.$195
  • plus $503 from 7 others

What the payments were for

  • Food & beverage$2,04292%
  • Education$1868%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,229 in reported general payments places this provider in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$16,343
Medicare patients
41
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate17$47,648
VraylarCariprazine Hcl31$39,802
Risperdal ConstaRisperidone Microspheres13$16,290
Clozapine90$6,931
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$3,252
Olanzapine25$3,013
Fluphenazine Decanoate17$2,228
Quetiapine Fumarate59$2,195
Aripiprazole50$2,000
Fluphenazine Hcl34$1,808
Haloperidol Decanoate21$1,281
Paliperidone ErPaliperidone11$1,147
Divalproex Sodium53$985
Naltrexone Hcl18$763
Hydroxyzine Hcl53$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$133$63,93830 claims
AbbVieVraylar$518$39,80231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Astoria

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →